Literature DB >> 12899501

Effects of probucol on endothelial damage by 5-fluorouracil.

Sara Kinhult1, Maria Albertsson, Jan Eskilsson, Magdalena Cwikiel.   

Abstract

Cardiotoxicity is a serious side effect of cancer treatment with the commonly used drug 5-fluorouracil (5-FU). The pathophysiology of this is unclear. Experimental studies show a thrombogenic effect of 5-FU, secondary to a direct toxic effect on the endothelium, possibly mediated by radical generation. Probucol is a lipid-lowering drug with strong antioxidant properties. The aim of this study was to evaluate the possibility of using probucol treatment to protect against the toxicity of 5-FU on vascular endothelium of the central artery in the ears of rabbits. Five groups of rabbits were treated with 1) 5-FU, 2) saline, 3) probucol high-dose and saline, 4) probucol high-dose and 5-FU, 5) probucol low-dose and 5-FU. Damage to the arterial endothelium was evaluated by scanning electron microscopy. Damage to the endothelium in 5-FU + probucol-treated animals was minimal and comparable to that of the control group. Intima disruption or thrombus formation was seen with 5-FU only. The results of the study indicate that treatment with probucol prevents 5-FU-induced endothelial injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12899501     DOI: 10.1080/02841860310004409

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  19 in total

Review 1.  Nonclinical aspects of venous thrombosis in pregnancy.

Authors:  Evi Struble; Wafa Harrouk; Albert DeFelice; Belay Tesfamariam
Journal:  Birth Defects Res C Embryo Today       Date:  2015-09-25

2.  Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient.

Authors:  Muhammad Wasif Saif; Komal Wasif; Harriette Butler-Bowen; Kenneth Miller; Robert B Diasio
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

Review 3.  The role of antioxidants in the era of cardio‑oncology.

Authors:  Duncan T Vincent; Yasmine F Ibrahim; Michael Graham Espey; Yuichiro J Suzuki
Journal:  Cancer Chemother Pharmacol       Date:  2013-12       Impact factor: 3.333

4.  Synthesis, characterization, antioxidant and anticancer activities of a new Schiff base and its M(II) complexes derived from 5-fluorouracil.

Authors:  Ahmet Savcı; Kenan Buldurun; Mehmet Eşref Alkış; Yusuf Alan; Nevin Turan
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

Review 5.  Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.

Authors:  Michael E Layoun; Chanaka D Wickramasinghe; Maria V Peralta; Eric H Yang
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

Review 6.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

7.  Critical limb ischaemia associated with chemotherapy for breast cancer.

Authors:  W V Garrett; J R I Brown; D Pickering; S M Andrews
Journal:  J R Soc Med       Date:  2004-09       Impact factor: 18.000

Review 8.  A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity.

Authors:  Anne Polk; Kirsten Vistisen; Merete Vaage-Nilsen; Dorte L Nielsen
Journal:  BMC Pharmacol Toxicol       Date:  2014-09-04       Impact factor: 2.483

9.  γ-Tocotrienol prevents 5-FU-induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5-FU-induced activation of Nrf2.

Authors:  Hideyuki Takano; Yukihiro Momota; Kouichi Kani; Keiko Aota; Yoshiko Yamamura; Tomoko Yamanoi; Masayuki Azuma
Journal:  Int J Oncol       Date:  2015-01-26       Impact factor: 5.650

10.  Myocardial infarction caused by pharmacological substances - case description and literature review.

Authors:  Tomasz Kameczura; Leszek Bryniarski; Sławomir Surowiec; Maryla Kocowska; Kalina Kawecka-Jaszcz; Danuta Czarnecka
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-09-16       Impact factor: 1.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.